Author name: korinek

Cambridge, MA, March 24, 2017 – Astrocyte Pharmaceuticals Inc., a CNS therapeutics startup, announced today that it has raised approximately $1.36M in a seed financing round.  The company is developing novel small molecule drugs that limit neuronal damage in patients that have suffered a stroke, traumatic brain injury (TBI) or concussion. The seed financing round […]

Cambridge, MA, October 19, 2015 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that David W. Wright, M.D., has joined the company’s Scientific Advisory Board. Astrocyte Pharmaceuticals is developing breakthrough small molecule therapeutics for acute administration to patients who have suffered a traumatic brain injury (TBI), concussion or stroke. “Dr. Wright is

Cambridge, MA, September 21, 2015 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that it has been awarded a Phase 1 Small Business Technology Transfer (STTR) Grant from the National Institutes of Health (NIH) to further evaluate and advance its promising drug candidate for traumatic brain injuries (TBI) and concussions. Astrocyte Pharmaceuticals

Cambridge, MA, July 16, 2015 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that Susan S. Margulies, Ph.D. has joined the company’s Scientific Advisory Board. Astrocyte Pharmaceuticals is developing breakthrough small molecule therapeutics for acute administration to patients who have suffered a traumatic brain injury (TBI), concussion or stroke. “Dr. Margulies is

Cambridge, Mass. (May 7, 2015) – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced it has entered into an exclusive worldwide licensing agreement with The University of Texas Health Science Center at San Antonio. The license grants Astrocyte Pharmaceuticals the exclusive use of patent rights owned by the UT Health Science Center and

Cambridge, Mass., May 1, 2015 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that Theodore E. Liston, Ph.D. has joined the company as Vice President of Pharmacokinetics and Pharmacodynamics (PK/PD). Astrocyte Pharmaceuticals is developing breakthrough small molecule therapeutics for acute administration to patients who have suffered a traumatic brain injury (TBI), concussion

The 5th Annual Traumatic Brain Injury (TBI) Conference is being held on April 15 and 16, 2015 in Washington DC. The conference will feature the latest research findings from many leading TBI researchers in the areas of neurotrauma, PTSD and concussion and presents an excellent opportunity to hear the latest updates in TBI. Dr. James

Cambridge, Mass., December 1, 2014 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Ives, Ph.D. has joined the company’s Board of Directors. Dr. Ives brings extensive scientific expertise in neuroscience, medicinal chemistry, drug metabolism and pharmacokinetics as well as broad business expertise in biotech partnerships, R&D operations, clinical development,